Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$17.4B
66M shares
52-week range
$186.05 – $282.15
56% from low
Exchange
NASDAQ
CS
P/S (TTM)
15.5
EV / FCF (TTM)
47.5
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
www.ascendispharma.comNo one on the platform currently holds ASND.
No tracked institution reports a position in ASND as of their last filing.
No one on the platform has traded ASND yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 90.2% | 150.9% | ||||
| Profit Margin % | -31.7% | -1277.5% | -2485.8% | |||
| Free Cash Flow Margin % | 6.3% | -1386.5% | -2143.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +1.6% on the P/E track.
At today's price, your expected annual return is +8.2% on the P/E track.
At today's price, your expected annual return is +14.6% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.4B | +92.9% | $14.37 | $10.84–$16.24 | 16.7× | 11 |
| 2027 | $2.0B | +47.0% | $9.15 | $4.27–$11.80 | 26.2× | 11 |
| 2028 | $2.5B | +26.7% | $14.61 | $7.22–$25.22 | 16.4× | 14 |
| 2029 | $3.0B | +19.6% | $17.88 | $16.36–$19.86 | 13.4× | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $1.71 | $3.29 | +92.4% |
| 2026-05-07 | $0.19 | $0.32 | +70.6% |
| 2026-02-11 | $-0.06 | $-0.64 | -966.7% |
| 2025-11-12 | $-0.41 | $-1.17 | -185.4% |
| 2025-08-07 | $-1.42 | $-0.93 | +34.5% |
| 2025-05-01 | $-1.56 | $-1.66 | -6.4% |
| 2025-02-12 | $-1.20 | $-0.68 | +43.3% |
| 2024-11-14 | $-1.83 |
| $-1.81 |
| +1.1% |
| $23.6B |
| — |
| IONSIonis Pharmaceuticals, Inc. | $47.25 | -8.15% | $7.9B | — |
| MDGLMadrigal Pharmaceuticals, Inc. | $523.26 | -3.11% | $12.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ASND will develop TransCon obesity and cardiometabolic programs itself after ending its $NVO collaboration and starting a $400M buyback. https://notreload.xyz/xy/ascendis-reclaims-obesity-rights-authorizes-400m-buyback/
View on StockTwits ↗
On watch for me, from the Top Tier Newswire AI model, these names haven't ran yet and are fresh candidates: $SGI $VRNS $ASND $LTGO
View on StockTwits ↗
$ASND $NVO $RANI Rani Therapeutics (NASDAQ: RANI) has positioned itself for massive market capture by appointing industry veteran Jesper Høiland as Head of Strategy. Leveraging over 30 years of expertise from Novo Nordisk and Ascendis Pharma, Høiland is pivoting Rani into the lucrative multi-billion-dollar obesity sector via its disruptive RaniPill® platform. The commercial thesis is rapidly validating. In July 2026, Rani announced breakthrough Phase 1 data for its weight-loss asset, RT-114, demonstrating an unprecedented bioavailability exceeding 150% compared to standard subcutaneous injections. Backed by Høiland’s elite network, Rani has secured high-value R&D partnerships with ProGen and PegBio. By successfully transforming painful GLP-1 injections into an oral blockbuster, Rani represents a highly lucrative, de-risked biotech growth opportunity.
View on StockTwits ↗
$ASND huge news today. $BMRN Is getting 20% but only until 2030.
View on StockTwits ↗
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged $ASND $BMRN https://stocktwits.com/news/equity/markets/asnd-bmrn-stocks-rise-street-calls-patent-peace-a-clean-overhang-lift-keep-ratings-unchanged/cZYzb98RJsM
View on StockTwits ↗
$BMRN (+1.3% pre) $ASND Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) https://ooc.bz/l/112762
View on StockTwits ↗$BMRN and $ASND end all Yuviwel patent fights. Ascendis will pay 20% on U.S. sales and 18% in the EU, Brazil, and South Korea until 2030. https://notreload.xyz/xy/biomarin-stock-jumps-after-settling-yuviwel-patent-fight-with-ascendis/
View on StockTwits ↗
$ASND New find from comparing shared picks by biotech hedge funds. The TransCon platform seems like a nice way to stamp out upgraded versions of existing drugs. Taking a small position here on Monday as a new long hold.
View on StockTwits ↗
Guggenheim⬆️ $AMLX's PT to $57 (from $55 prior) due to⬆️avexitide PoS (95% from 90% prior)—sees significant⬆️pot'l to its valuation. $RYTM $ASND MBX VOGX RICFY ZLDPF ZLDPY RZLT Here's what Guggenheim said: https://x.com/Quantumup1/status/2092944835665650096?s=20
View on StockTwits ↗
$ASND Not the most exciting name but has been solid, I’d guess $275 into 2027
View on StockTwits ↗BMO Capital starts coverage on $ALNY, $ASND, $BMRN, $CATX & more with Outperform ratings and price targets. See full analyst insights and targets. https://notreload.xyz/xy/bmo-capital-initiates-coverage-on-7-biotech-stocks/
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.